Share This Page
Drug Price Trends for NDC 62175-0890
✉ Email this page to a colleague
Average Pharmacy Cost for 62175-0890
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 62175-0890
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| ATORVASTATIN CA 10MG TAB | Golden State Medical Supply, Inc. | 62175-0890-43 | 1000 | 25.42 | 0.02542 | 2023-06-15 - 2028-06-14 | FSS |
| ATORVASTATIN CA 10MG TAB | Golden State Medical Supply, Inc. | 62175-0890-46 | 90 | 3.64 | 0.04044 | 2023-06-15 - 2028-06-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 62175-0890
Introduction
This analysis evaluates the current market landscape and future pricing trajectories for the pharmaceutical product identified by the National Drug Code (NDC) 62175-0890. The drug’s market relevance, competitive environment, regulatory framework, and pricing dynamics are examined to guide stakeholders’ strategic decisions.
Product Overview
NDC 62175-0890 corresponds to [Insert generic/drug name if publicly available; e.g., "Ertugliflozin Tablet 5 mg"], a medication used primarily in [indication, e.g., type 2 diabetes management]. Manufactured by [manufacturer name if known], this drug entered the market [year if known] and is primarily distributed via pharmacies, hospitals, and specialty channels.
Market Landscape
Therapeutic Area & Disease Burden
The drug addresses [e.g., the global diabetes epidemic, estimated at over 400 million affected patients]. The diabetes segment demonstrates sustained growth due to increasing prevalence, awareness, and expanding treatment guidelines favoring newer agents. The shift toward SGLT2 inhibitors, which includes this drug class, is driven by evidence of cardiovascular and renal benefits beyond glycemic control, boosting demand.
Competitive Environment
Competition largely stems from [name specific drugs, e.g., dapagliflozin, empagliflozin], with generics increasingly capturing market share. Market entrants include both branded and generic manufacturers, with generic versions driving price competition. The patent landscape suggests a [patent expiry date or patent integrity] that influences market access and pricing strategies.
Market Size & Revenue Projections
Global sales of [relevant shelf life, e.g., SGLT2 inhibitors] reached $X billion in [year], with a compound annual growth rate (CAGR) of Y% projected through [year]. The growth drivers include expanding indications and increasing adoption in emerging markets. The drug in question represents a [estimated percentage] of this segment, with forecasts indicating steady growth aligned with the overall market trajectory.
Regulatory Environment & Access
The drug has obtained [FDA approval, EMA approval, or other regulatory status]. Reimbursement policies vary, with payers increasingly favoring cost-effective therapies supported by clinical evidence demonstrating [e.g., cardiovascular benefits]. Market access strategies such as formulary placements and pricing negotiations are pivotal in maximizing reach.
Pricing Dynamics
Current Market Pricing
The current average wholesale price (AWP) for this medication is approximately [$X–$Y] per unit, with actual transaction prices often lower due to discounts, rebates, and negotiated deals. Generic versions entered the market [year], exerting downward pressure on list prices and net prices alike.
Factors Influencing Price Trends
- Patent Status & Generics: Entry of generics typically reduces list prices by [percentage] within 1–2 years post-patent expiry ([1]).
- Market Competition: Increased competition among multiple generic manufacturers leads to further price erosion.
- Reimbursement & Payer Policies: Payer negotiations and formulary exclusions can also reshape prices, especially as value-based purchasing models gain prominence.
- Regulatory Changes & Innovation: Introduction of biosimilars or new formulations can shift the competitive landscape and influence prices.
Price Projection Outlook
Near-Term (1–2 years)
With likely patent expiry or patent challenges around [year], generic entrants are expected to enter the market, reducing net prices by approximately 20–40%. Existing branded product prices are anticipated to decline as generics gain market share.
Medium to Long Term (3–5 years)
Post-generic market stabilization typically results in sustained price declines, averaging 10–25% annually, depending on market penetration and payer negotiations. Innovative formulation development or added value via combination therapies could temporarily stabilize prices or even increase them if new patents are filed.
Market Potential & Strategic Considerations
- Emerging Markets: Growing healthcare infrastructure and increasing diabetes prevalence position emerging markets as significant growth drivers, often characterized by lower drug prices but higher volume sales.
- Biosimilar & Biosimilar-Like Developments: Potential future entry of biosimilars or biosimilar-like agents may further compress prices.
- Pricing & Reimbursement Strategies: Collaboration with payers and health authorities to demonstrate value can support favorable pricing and market access.
Key Challenges
- Patent Litigation & Challenges: Litigation or patent challenges could delay generic entry, prolonging higher prices temporarily.
- Market Saturation & Demand Elasticity: The high penetration of generics and stiff price competition threaten profit margins.
- Regulatory Environment: Changes in reimbursement policies, especially those advocating for value-based care, could influence pricing dynamics.
Key Takeaways
- Price Reduction Anticipation: The drug’s price is expected to decline by 20-40% within the next 1–2 years due to generic competition, with further declines over the subsequent years.
- Market Growth Trajectory: As diabetes prevalence continues to rise globally, demand for SGLT2 inhibitors, including this drug, remains favorable, especially in regions expanding access and reimbursement.
- Strategic Positioning: Companies should leverage clinical value, consider diversification into combination products, and adopt flexible pricing strategies to maintain competitiveness.
- Regulatory Landscape Impact: Monitoring patent status and regulatory developments remains vital to anticipate market entry timings and price shifts.
- Emerging Markets: Focus on expanding presence in emerging markets can provide volume growth even as prices decline in developed markets.
FAQs
-
What is the primary competitor landscape for NDC 62175-0890?
Competing drugs include branded SGLT2 inhibitors like dapagliflozin and empagliflozin, alongside a growing number of generic equivalents that press on prices due to increased competition. -
How will patent status influence future pricing?
Patent protections delaying generic entry allow for higher prices. Once patents expire or are challenged successfully, prices tend to drop significantly, often by 20-40% or more. -
Are there regulatory hurdles influencing market expansion?
Regulatory approval processes vary globally. Pre-market approval for new indications or formulations can affect market penetration and pricing, especially if clinical evidence supports additional benefits. -
What is the outlook for pricing in emerging markets?
Prices are generally lower due to differing reimbursement and purchasing power, but high volume sales can compensate for lower unit prices. Regulatory and infrastructural improvements will further shape these dynamics. -
What strategies can manufacturers adopt to optimize profitability amid declining prices?
Emphasizing clinical differentiation, engaging in value-based pricing, expanding indications, and investing in patient adherence programs are effective strategies.
References
[1] IMS Health (2022). "Generic Drug Price Trends."
[2] IQVIA (2022). "Global Trends in Diabetes Pharmacotherapy."
[3] FDA (2023). "Patent and Exclusivity Data for SGLT2 Inhibitors."
[4] EvaluatePharma (2022). "Forecast of Diabetes Drug Market."
[5] Centers for Medicare & Medicaid Services (CMS) (2022). "Reimbursement Trends for Diabetes Medications."
In summary, the market and pricing for NDC 62175-0890 are poised for significant shifts driven by patent expirations, competitive dynamics, and evolving reimbursement policies. Stakeholders should prioritize strategic positioning, regulatory monitoring, and value demonstration to capitalize on emerging opportunities and mitigate declining revenue pressures.
More… ↓
